All
Phase 4 study reaffirms safety of low-dose acitretin
September 1st 2006Results of a phase 4, open-label, multicenter study indicate that low-dose acitretin (Soriatane, Connetics) in moderate to severe psoriasis patients provides efficacy as monotherapy by 24 weeks, but requires patience, said Gerald G. Krueger, M.D., at the American Academy of Dermatology's Academy '06.
Target retirement funds offer new options for busy investors
September 1st 2006Every fund has to pay its managers and cover normal operating expenses. That's where the annual management fee comes in. Whatever the rate of return generated by the fund, it will be reduced by the amount of the annual fee.
Sculptra tips include enforcing 'Rule of Fives,' combining with temporary fillers
September 1st 2006National report - Poly-L-lactic acid filler Sculptra (Dermik) can offer some excellent long-term results in adding volume when patients have facial lipoatrophy, and Cherie Ditre, M.D., offers some key tips to further enhance successful use of the filler.
Talk on cutaneous mucinoses revisits lichen myxedematosus
September 1st 2006London - Lichen myxedematosus (LM) is not a single disease, but represents two clinicopathologic subsets that are important to distinguish because they differ with respect to prognosis and treatment, said Franco Rongioletti, M.D., at the annual meeting of the European Association of Dermatology and Venereology.
Fungal Infections: Current therapies, solutions
September 1st 2006San Diego - A multitude of fungi live in our ecosystem, and we can hope for peaceful coexistence with them - staying free from infection - but this is not always the rule. Sometimes when the immune system takes a turn for the worse fungi seize the opportunity to multiply and clinical presentation is the result.
Total body photography not standard of care
September 1st 2006Eckley M. Keach's article in the June 2006 issue of Dermatology Times ("Successful malpractice defense lies in body of evidence") provides tips for dermatologists to reduce the risk of malpractice liability from treating high-risk melanoma patients.
Managing rosacea: Practitioners discuss trends
September 1st 2006I recently moderated numerous advisory panels during which we spoke to 226 practicing specialists in the field of dermatology on the topic of rosacea management. The panels were conducted across the United States and included dermatologists, nurse practitioners and physician assistants. We met in small groups, mixing didactic presentations with open-ended discussions. We discussed a wide array of topics, from the history of rosacea therapies in the United States to new frontiers for topical treatments.
Medical practice from both sides now
September 1st 2006My professional life has changed radically over the past several months. I have left academic medicine and have started a private practice. Living in the professional cocoon of the university, I had absolutely no idea of the complexities, pressures, anxieties and great joy associated with this enterprise. I never dreamed that I would be paying a practice management consultant, a phone installation consultant, an employee health insurance agent, a computer consultant, an office security consultant, a janitorial consultant and the credit card processing company sales associate to provide advice.
AAD hopes iPledge survey will prompt program changes
September 1st 2006Schaumburg, Ill. -- The American Academy of Dermatology (AAD) hopes results of its recent iPLEDGE survey will prompt changes in the federal isotretinoin registry, which doctors and patients say is cumbersome and frustrating and hampers the delivery of quality medical care.
Study reports effectiveness of diphencyprone in palmoplantar-wart treatment
August 4th 2006Parkville, Victoria, Australia -- Researchers here report that patient-applied ointment comprising 0.1 percent diphencyprone and 15 percent salicylic acid in white soft paraffin is effective in treating palmoplantar warts.
FDA approves sunscreen product containing previously banned ingredient
August 4th 2006Washington -- In a move considered by many to be long overdue, the Food and Drug Administration (FDA) has approved a sunscreen product that contains Mexoryl, an ingredient considered to be more effective than other filters in protecting the skin against the sun's potentially damaging UVA rays.
Improving treatments HELP rosacea sufferers
August 1st 2006National report - While rosacea remains incurable for the estimated 14 million people who suffer from the condition, treatment options are evolving to provide dermatologists with a more effective armamentarium in helping to control the condition.
Benefits of metronidazole gel for rosacea treatment
August 1st 2006National report - Results of a phase 3B study comparing once daily treatment with the new 1 percent metronidazole gel (MetroGel, Galderma) and twice daily application of 15 percent azelaic acid gel (Finacea, Intendis) demonstrate that the two products have statistically similar efficacy, safety and tolerability in the treatment of moderate papulopustular acne, says John E. Wolf, Jr., M.D., professor and chairman, department of dermatology, Baylor College of Medicine, Houston.
Oral, anti-inflammatory rosacea drug: Effective, safe, approved
August 1st 2006Las Vegas - Rosacea treatment has taken a giant step forward with the Food and Drug Administration's recent approval of Oracea - doxycycline controlled-release capsules made by CollaGenex Pharmaceuticals. Oracea is the first FDA-approved, orally administered, systemically delivered drug to treat rosacea. It was approved for the treatment of inflammatory papules and pustules of rosacea in adult patients, and is currently available to dermatologists.
CDC to investigate mysteries of Morgellons disease
August 1st 2006Atlanta - The federal government's Centers for Disease Control and Prevention has announced that it will begin investigating a mysterious disease for which no cause has been identified - and which most medical professionals, including dermatologists, believe isn't a disease at all, but a psychotic disorder.
Field therapy important complement for optimal treatment of AKs
August 1st 2006Baltimore - Treatment for persons with numerous actinic keratoses (AKs) in an area of severely sun-damaged skin should include field therapy that can clear both the clinically evident lesions and sub-clinical danger spots, according to Anthony A. Gaspari, M.D., speaking at the East Coast Dermatology Seminar, here.